FINWIRES · TerminalLIVE
FINWIRES

Whitehawk Therapeutics' Antibody Drug Conjugates Indicate Potential Efficacy Against Cancer, Oppenheimer Says

By

Whitehawk Therapeutics (WHWK) presented "solid" preclinical datasets for its early stage antibody drug conjugates, or ADCs, indicating "substantial clinical evidence" of their potential efficacy against solid tumor targets, Oppenheimer said in a Monday note.

Out of the company's portfolio of ADCs, HWK-007 and HWK-016 are currently under clinical studies and HWK-206 is expected to follow in Q3, the note said.

HWK-007, which targets Protein Tyrosine Kinase 7 or PTK7, demonstrated "potent activity," while HWK-016 showed "clear superiority" to an earlier ADC targeting Mucin 16 or MUC16, Oppenheimer said. HWK-206 also showed enhanced properties against Seizure-Related Homolog Protein 6 or SEZ6, the firm added.

Oppenheimer has an outperform rating and $5 price target on Whitehawk Therapeutics.

Price: $4.21, Change: $-0.02, Percent Change: -0.47%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB